173.02
+1.02(+0.59%)
Currency In USD
| Previous Close | 172 |
| Open | 170.19 |
| Day High | 174.34 |
| Day Low | 170.19 |
| 52-Week High | 183 |
| 52-Week Low | 111.09 |
| Volume | 53,802 |
| Average Volume | 506,372 |
| Market Cap | 10.45B |
| PE | -25.98 |
| EPS | -6.66 |
| Moving Average 50 Days | 166.64 |
| Moving Average 200 Days | 145.54 |
| Change | 1.02 |
If you invested $1000 in Ascendis Pharma A/S (ASND) 10 years ago, it would be worth $9,382.86 as of July 02, 2025 at a share price of $173.02. Whereas If you bought $1000 worth of Ascendis Pharma A/S (ASND) shares 5 years ago, it would be worth $1,145.83 as of July 02, 2025 at a share price of $173.02.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
TransCon® hGH Boosted Treatment Benefits of TransCon® CNP in Children with Achondroplasia at Week 26 Interim Analysis of the Phase 2 COACH Trial
GlobeNewswire Inc.
Jun 09, 2025 11:00 AM GMT
- For the TransCon CNP treatment-naïve cohort, combination treatment resulted in mean annualized growth velocity (AGV) of 9.14 cm/year, with an improvement in mean ACH height Z-score of +0.53 over 26 weeks - For the TransCon CNP-treated cohort, combi
FDA Accepts TransCon® CNP NDA for Priority Review
GlobeNewswire Inc.
Jun 02, 2025 12:00 PM GMT
– Once-weekly TransCon CNP demonstrated significantly higher annualized growth velocity, the primary endpoint, compared to placebo – Multiple benefits beyond linear growth were observed compared to placebo, with a safety and tolerability profile simi
New Data Shows Improvements in Growth and Bone Morphometry in Children with Achondroplasia Treated with TransCon® CNP (Navepegritide)
GlobeNewswire Inc.
May 13, 2025 8:01 PM GMT
COPENHAGEN, Denmark, May 13, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new data showing improvements in growth and bone morphometry from Week 52 of its pivotal ApproaCH Trial of TransCon CNP (navepegritide) in chil